Company intelligence / Profile preview
Valdospan
Madrid, Madrid, Spainservier.es ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Valdospan is a pharmaceutical entity based in Spain that operates as a subsidiary of the Servier Group. The company is primarily associated with the commercialization and distribution of agomelatine (marketed under brand names such as Valdoxan and Thymanax) within the Spanish market. Agomelatine is a melatonergic antidepressant used for the treatment of major depressive episodes in adults, functioning as a melatonin receptor agonist and a selective serotonin receptor antagonist. Valdospan supports Servier's broader mission in the central nervous system therapeutic area by managing local regulatory and commercial operations for these psychiatric treatments.
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecule
- Industry
- Pharma
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Valdospan.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Valdospan.